Elranatamab in Relapsed/Refractory Multiple Myeloma
This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.
Multiple Myeloma
DRUG: Elranatamab
MRD negativity rate as best response, MRD negativity rate as best response, 1 year of starting treatment
Sustained MRD negativity rate at 10^-5, Sustained MRD negativity rate at 10\^-5, Through study completion, up to 5 years|Overall response rate, Overall response rate, Within 1 year of treatment|Complete response rate, Complete response rate, Within 1 year of treatment|Progression free survival, Progression free survival, Through study completion, up to 5 years|Duration of response, Duration of response, Through study completion, up to 5 years|Safety (cytokine release syndrome, neurotoxicity, treatment-related adverse events), Number of participants with cytokine release syndrome, neurotoxicity, treatment-related adverse events as assessed by CTCAE v5.0, Through study completion, on average 4 weeks (cytokine release syndrome, neurotoxicity); Through study completion, up to 5 years (treatment-related adverse events as assessed by CTCAE v5.0 )|Quality of life (questionnaire and by EORTC QLQ-MY20 questionnaire), Quality of life assessed by cancer therapy satisfaction questionnaire and by EORTC QLQ-MY20 questionnaire, Through study completion, up to 5 years
Soluble BCMA, T-cell immune phenotype, Soluble BCMA, T-cell immune phenotype, 1 year|Overall MRD negativity rate at 10^-6, Overall MRD negativity rate at 10\^-6, 1 year
Phase II study of elranatamab in patients with relapsed/refractory multiple myeloma who has received 1 to 3 prior lines of therapy. Patients may enter treatment-free observation period if they have a sustained MRD negative response for greater than 12 months.